Loading organizations...
§ Private Profile · Vancouver, BC, Canada
Precision biotechnology accelerating oncology drug discovery using cryo-EM and AI for protein interaction therapeutics.
Gandeeva Therapeutics is a precision biotechnology company based in Burnaby, British Columbia, that utilizes cryogenic electron microscopy and artificial intelligence to accelerate drug discovery and development. The enterprise focuses on analyzing protein interactions at an atomic resolution to engineer novel therapeutics, primarily targeting oncology and precision medicine applications. The venture-backed firm has raised $40 million in Series A funding to scale its internal operations across structural biology, computer science, and medicinal chemistry. This financing was co-led by Lux Capital and Leaps by Bayer, with additional participation from prominent backers including Amgen Ventures and Obvious Ventures. Operating as a spin-off from the University of British Columbia, the organization previously published the first atomic-level analysis of spike proteins from major COVID-19 variants during the global pandemic. Gandeeva Therapeutics was founded in 2021 by Dr. Sriram Subramaniam.
Gandeeva Therapeutics has raised $40.0M across 1 funding round.
Gandeeva Therapeutics has raised $40.0M in total across 1 funding round.
Gandeeva Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $40M Series A | Juergen Eckhardt, Adam Goulburn | Dimension Capital, OrbiMed, Polaris Partners, Section 32, AIR Street Capital, Amgen Ventures, Amplitude Ventures, Obvious Ventures | Announced |
Gandeeva Therapeutics has raised $40.0M in total across 1 funding round.
Gandeeva Therapeutics's investors include Juergen Eckhardt, Adam Goulburn, Dimension Capital, OrbiMed, Polaris Partners, Section 32, Air Street Capital, Amgen Ventures, Amplitude Ventures, Obvious Ventures.
Gandeeva Therapeutics is a precision biotechnology company founded in 2021 and based in Burnaby, Vancouver, Canada, that develops novel therapies targeting protein interactions, primarily in oncology.[1][2][3][5] It leverages a proprietary platform combining cryogenic electron microscopy (cryo-EM) and artificial intelligence (AI)/machine learning to enable atomic-resolution imaging of protein-drug interactions, accelerating drug discovery for challenging diseases like cancer.[1][2][3] The company serves patients with hard-to-treat conditions by creating proximity-inducing small molecules (e.g., protein glues), engineered antibodies, and other precision medicines, solving the problem of targeting complex protein functions that drive diseases.[2][3][4] With a $40M Series A funding round in 2024 led by Lux Capital and Leaps by Bayer, Gandeeva demonstrates strong early momentum, advancing a preclinical pipeline including VCP inhibitors and other chemical/small molecule drugs in oncology.[3][4]
Gandeeva Therapeutics was founded in 2021 by Dr. Sriram Subramaniam, a renowned structural biologist from the University of British Columbia (UBC), who serves as CEO and is celebrated for pioneering the cryo-EM resolution revolution and innovations in 3D electron microscopy.[1][3][5] Subramaniam's background includes leading UBC's advanced cryo-EM lab, where his team pivoted during the COVID-19 pandemic to publish the first atomic-level analyses of spike proteins from variants like Alpha and Omicron, revealing viral infection mechanisms.[1] This expertise spun out into Gandeeva, integrating cryo-EM with AI to transform structural biology for drug design, building on decades of research into protein folding and native cellular contexts implicated in diseases.[3] Early traction came from assembling an interdisciplinary team of structural biologists, computer scientists, medicinal chemists, and biotech veterans, culminating in the landmark Series A raise to scale the platform.[2][3]
Gandeeva stands out in biotech through its integrated technology stack and focus on atomic-scale precision:
Gandeeva rides the convergence of AI-driven structural biology and cryo-EM advancements, trends exploding since the 2017 Nobel for cryo-EM and AI tools like AlphaFold, enabling unprecedented visualization and prediction of protein dynamics in disease.[1][3] Timing is ideal amid a precision oncology boom, where protein degradation and proximity modulation (e.g., PROTACs/glue tech) address "undruggable" targets driving 80-90% of cancers, fueled by market forces like rising VC interest in AI-biotech (e.g., its $40M Series A) and regulatory pushes for faster drug development.[2][3][4] It influences the ecosystem by democratizing atomic-scale insights—previously lab-bound—scaling drug discovery for academia, pharma partners, and spinouts, while advancing from COVID pivots to oncology, potentially reshaping how biotech tackles proteinopathies in cancer, neurodegeneration, and beyond.[1][2]
Gandeeva is poised to advance its preclinical oncology pipeline into IND-enabling studies, leveraging Series A funds to expand AI-cryo-EM automation for more modalities like biologics and new indications.[3][4] Key trends like multimodal AI integration and high-res structural data will accelerate its hit-to-lead timelines, potentially yielding first-in-class protein glues amid a $100B+ oncology market hungry for targeted therapies. Its influence may grow through strategic partnerships (e.g., with Bayer, Amgen Ventures) and talent recruitment, evolving from UBC spinout to platform leader in atomic-precision drugging—unlocking therapies that transform patient outcomes in the most intractable diseases.[2][3] This positions Gandeeva as a biotech innovator where technology meets unmet need.